Good Life Advisors LLC Makes New $443,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Good Life Advisors LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,870 shares of the medical research company’s stock, valued at approximately $443,000.

Several other institutional investors have also recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of IQVIA in the third quarter valued at approximately $379,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in shares of IQVIA by 20.4% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 5,719 shares of the medical research company’s stock valued at $1,355,000 after buying an additional 968 shares during the period. Sumitomo Life Insurance Co. increased its stake in shares of IQVIA by 1.4% in the third quarter. Sumitomo Life Insurance Co. now owns 10,068 shares of the medical research company’s stock valued at $2,386,000 after buying an additional 140 shares during the period. Swedbank AB increased its stake in shares of IQVIA by 0.9% in the third quarter. Swedbank AB now owns 91,489 shares of the medical research company’s stock valued at $21,680,000 after buying an additional 786 shares during the period. Finally, Creative Planning increased its stake in shares of IQVIA by 17.8% in the third quarter. Creative Planning now owns 21,013 shares of the medical research company’s stock valued at $4,980,000 after buying an additional 3,176 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Argus raised IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Robert W. Baird upped their target price on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. JPMorgan Chase & Co. upped their target price on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Monday, October 14th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $267.87.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

IQVIA stock opened at $236.69 on Friday. The stock has a market capitalization of $43.15 billion, a price-to-earnings ratio of 30.74, a PEG ratio of 2.22 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock’s 50 day moving average price is $239.08 and its two-hundred day moving average price is $231.16. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period last year, the business earned $2.22 EPS. IQVIA’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.